Meeting
2018 ASCO Annual Meeting
Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Authors
Saad Zafar Usmani
Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC
Saad Zafar Usmani , Maria-Victoria Mateos , Nizar J. Bahlis , Sebastian Grosicki , Andrew Spencer , Rajesh Bandekar , Tara J. Masterson , Pamela L. Clemens , Christoph Johann Heuck , Ming Qi , Hareth Nahi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03277105
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8058)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8058
Abstract #
TPS8058
Poster Bd #
65b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Corticosteriod tapering in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) receiving subcutaneous daratumumab (DARA SC): Part 3 of the open-label, multicenter, phase Ib PAVO Study.
First Author: Hareth Nahi
Poster
2018 ASCO Annual Meeting
Pomalidomide and dexamethasone (pom-dex) with or without daratumumab (DARA) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): A multicenter, randomized, phase 3 study (APOLLO).
First Author: Pieter Sonneveld
Poster
2018 ASCO Annual Meeting
Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
First Author: Ajai Chari
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau